Recombinant Human IL-18 BPa Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IL-18 BPa Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit the IL-18-induced response of KG‑1 human acute myelogenous leukemia cells. The ED₅₀ for this effect is 0.02‑0.12 µg/mL in the presence of 40 ng/mL of recombinant human IL-18.
• Source: Mouse myeloma cell line, NS0-derived human IL-18 BPa protein
  

  Human IL-18 Bpa (Thr29-Gly192) Accession # AAD17190	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: AAD17190
• N-terminal Sequence: Thr29
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: IL18BP
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 44.2 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-80 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-18 BPa Fc Chimera Protein, CF

• IL18 BPa
• IL-18 BPa
• IL18BP
• IL-18BP
• IL18BPa
• interleukin 18 binding protein
• interleukin-18-binding protein
• MC51L-53L-54L homolog gene product
• tadekinig-alfa

Background

Interleukin 18 binding protein (IL-18 BP) is a secreted glycoprotein, which functions as an IL-18 antagonist by binding to IL-18 and blocking its biological activity. IL‑18 BP bears no amino acid sequence homology to the membrane-associated IL-18 and IL-1 receptor proteins. The gene for human IL-18 BP has been localized to chromosome 11q13. It encodes for at least four isoforms by alternative splicing. The IL-18 BP isoforms a and c each contain one immunoglobulin (Ig)-like C2-type domain while isoforms b and d lack a complete Ig domain. The complete Ig domain has been shown to be essential to the binding and neutralizing properties of the binding proteins. Two isoforms of mouse IL18 BP (c and d) containing the complete Ig domain have also been isolated and shown to neutralize IL-18 bioactivity. Human and mouse IL-18 BPs share approximately 61% amino acid sequence identity. Several poxviruses also encode proteins with sequence similarity to the human and mouse IL-18 BP. Viral IL-18 BPs have been shown to bind and inhibit IL-18 responses and may be involved in modulating host immune responses. The expression of IL-18 BP is markedly up-regulated by IFN-gamma , suggesting that IL-18 activity is modulated by a negative feedback mechanism mediated by IL-18 BP.

1. Mühl, H. et al. (2000) Biochem. Biophys. Res. Commun. 267:960.
2. Kim, S-H. et al. (2000) Proc. Nat. Acad. Sci. USA 97:1190.
3. Calderara, S. et al. (2001) Virology 279:22.

Publications for IL-18 BPa/IL18BP (119-BP)(13)

Publications using 119-BP

• Higashi, Y;Dashek, R;Delafontaine, P;Rector, RS;Chandrasekar, B; EF24, a Curcumin Analog, Reverses Interleukin-18-Induced miR-30a or miR-342-Dependent TRAF3IP2 Expression, RECK Suppression, and the Proinflammatory Phenotype of Human Aortic Smooth Muscle Cells Cells 2024-10-10 [PMID: 39451191] (Bioassay, Human)
• Menachem, A;Alteber, Z;Cojocaru, G;Fridman Kfir, T;Blat, D;Leiderman, O;Galperin, M;Sever, L;Cohen, N;Cohen, K;Granit, RZ;Vols, S;Frenkel, M;Soffer, L;Meyer, K;Menachem, K;Galon Tilleman, H;Morein, D;Borukhov, I;Toporik, A;Perpinial Shahor, M;Tatirovsky, E;Mizrachi, A;Levy-Barda, A;Sadot, E;Strenov, Y;Eitan, R;Jakobson-Setton, A;Yanichkin, N;Ferre, P;Ophir, E; Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects Cancer immunology research 2024-04-01 [PMID: 38592331] (Bioassay, Human)
• Cui, W;Hull, L;Zizzo, A;Wang, L;Lin, B;Zhai, M;Kumar, VP;Xiao, M; The Roles of IL-18 in a Realistic Partial Body Irradiation with 5% Bone Marrow Sparing (PBI/BM5) Model Toxics 2023-12-20 [PMID: 38276718] (In Vivo, Mouse, Transgenic Mouse)
• W Cui, L Hull, A Zizzo, L Wang, B Lin, M Zhai, M Xiao Pharmacokinetic Study of rhIL-18BP and Its Effect on Radiation-Induced Cytokine Changes in Mouse Serum and Intestine Toxics, 2022-12-30;11(1):. 2022-12-30 [PMID: 36668761] (In Vivo, Mouse)
• M Nayrac, M Requena, C Loiseau, M Cazabat, B Suc, N Carrere, K Barange, L Alric, G Martin-Blo, J Izopet, P Delobel Th22 cells are efficiently recruited in the gut by CCL28 as an alternative to CCL20 but do not compensate for the loss of Th17 cells in treated HIV-1-infected individuals Mucosal Immunol, 2020-04-28;0(0):. 2020-04-28 [PMID: 32346082] (Bioassay, Human)
• ES Weiss, C Girard-Guy, D Holzinger, AA de Jesus, Z Tariq, J Picarsic, EJ Schiffrin, D Foell, AA Grom, S Ammann, S Ehl, T Hoshino, R Goldbach-M, C Gabay, SW Canna Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome Blood, 2018-01-11;0(0):. 2018-01-11 [PMID: 29326099] (Multiplex Standard, Human)
• E Briend, GJ Ferguson, M Mori, G Damera, K Stephenson, NA Karp, S Sethi, CK Ward, MA Sleeman, JS Erjefält, DK Finch IL-18 associated with lung lymphoid aggregates drives IFN? production in severe COPD Respir. Res., 2017-08-22;18(1):159. 2017-08-22 [PMID: 28830544] (Bioassay, Human)
• Characterization of the Inflammasome in Human Kupffer Cells in Response to Synthetic Agonists and Pathogens J Immunol, 2016-05-25;0(0):. 2016-05-25 [PMID: 27226092] (Bioassay, Human)
• Pro-inflammatory interleukin-18 increases Alzheimer&#039;s disease-associated amyloid-beta production in human neuron-like cells. J Neuroinflammation, 2012-08-16;9(0):199. 2012-08-16 [PMID: 22898493] (Bioassay, Human)
• Venkatesan B, Valente AJ, Reddy VS, Siwik DA, Chandrasekar B Resveratrol blocks interleukin-18-EMMPRIN cross-regulation and smooth muscle cell migration. Am. J. Physiol. Heart Circ. Physiol., 2009-06-26;297(2):H874-86. 2009-06-26 [PMID: 19561311] (Neutralization, Human)
• Nazarian SH, Rahman MM, Werden SJ, Villeneuve D, Meng X, Brunetti C, Valeriano C, Wong C, Singh R, Barrett JW, Xiang Y, McFadden G Yaba monkey tumor virus encodes a functional inhibitor of interleukin-18. J. Virol., 2007-10-24;82(1):522-8. 2007-10-24 [PMID: 17959666] (Surface Plasmon Resonance, Human)
• Felderhoff-Mueser U, Sifringer M, Polley O, Dzietko M, Leineweber B, Mahler L, Baier M, Bittigau P, Obladen M, Ikonomidou C, Buhrer C Caspase-1-processed interleukins in hyperoxia-induced cell death in the developing brain. Ann. Neurol., 2005-01-01;57(1):50-9. 2005-01-01 [PMID: 15622543] (In Vivo, Rat)
• Wu C, Sakorafas P, Miller R, McCarthy D, Scesney S, Dixon R, Ghayur T IL-18 receptor beta-induced changes in the presentation of IL-18 binding sites affect ligand binding and signal transduction. J. Immunol., 2003-06-01;170(11):5571-7. 2003-06-01 [PMID: 12759435] (Binding Assay, Human)

Bioinformatics

• Gene Symbol: IL18BP
• Uniprot:
  • AAD17190()